ATE103932T1 - Fusionsprotein bestehend aus gm-csf und il-3. - Google Patents

Fusionsprotein bestehend aus gm-csf und il-3.

Info

Publication number
ATE103932T1
ATE103932T1 AT90914297T AT90914297T ATE103932T1 AT E103932 T1 ATE103932 T1 AT E103932T1 AT 90914297 T AT90914297 T AT 90914297T AT 90914297 T AT90914297 T AT 90914297T AT E103932 T1 ATE103932 T1 AT E103932T1
Authority
AT
Austria
Prior art keywords
csf
fusion protein
protein consisting
alone
combined
Prior art date
Application number
AT90914297T
Other languages
English (en)
Inventor
Benson M Curtis
Linda S Park
David J Cosman
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE103932T1 publication Critical patent/ATE103932T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT90914297T 1989-08-22 1990-08-14 Fusionsprotein bestehend aus gm-csf und il-3. ATE103932T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39714689A 1989-08-22 1989-08-22
PCT/US1990/004599 WO1991002754A1 (en) 1989-08-22 1990-08-14 Fusion proteins comprising gm-csf and il-3

Publications (1)

Publication Number Publication Date
ATE103932T1 true ATE103932T1 (de) 1994-04-15

Family

ID=23570012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90914297T ATE103932T1 (de) 1989-08-22 1990-08-14 Fusionsprotein bestehend aus gm-csf und il-3.

Country Status (11)

Country Link
EP (1) EP0489116B1 (de)
JP (1) JP3115318B2 (de)
AT (1) ATE103932T1 (de)
AU (1) AU632372B2 (de)
DD (1) DD297188A5 (de)
DE (1) DE69007975T2 (de)
DK (1) DK0489116T3 (de)
ES (1) ES2055445T3 (de)
FI (1) FI920764A0 (de)
NO (1) NO301888B1 (de)
WO (1) WO1991002754A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129697T3 (de) * 1990-08-29 2004-01-29 Inst Genetics Llc Aus mehreren domänen bestehende hämatopoese-stimulatoren
EP0503050A4 (en) * 1990-09-28 1994-07-06 Ortho Pharma Corp Hybrid growth factors
AU664030B2 (en) * 1991-02-27 1995-11-02 Micromet Ag Serine-rich peptide linkers
JP3417558B2 (ja) 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
WO1993005169A1 (en) * 1991-08-30 1993-03-18 Fred Hutchinson Cancer Research Center Hybrid cytokines
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
ATE251669T1 (de) 1992-11-24 2003-10-15 Searle & Co Mutierte polypeptide des interleukin-3(il-3)
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
AU686840B2 (en) * 1994-07-07 1998-02-12 Immunex Corporation Fusion proteins comprising GM-CSF and antigens and their expression in yeast
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
CA2789515A1 (en) * 2010-02-18 2010-08-26 Csl Limited Treatment of chronic inflammatory conditions
JP6416628B2 (ja) 2012-01-20 2018-10-31 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 標的変異体αヘリックスバンドルサイトカイン
ES2657060T3 (es) * 2013-07-18 2018-03-01 Vib Vzw Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas
MX2016000721A (es) 2013-07-19 2016-09-07 Vib Vzw Direccionamiento de antagonistas de citocinas.
KR102268688B1 (ko) 2013-07-19 2021-06-24 브이아이비 브이지더블유 표적화된 변형된 tnf 패밀리 구성원
US9932409B2 (en) 2013-07-19 2018-04-03 Vib Vzw Targeted modified IL-1 family members
JP6067540B2 (ja) * 2013-11-07 2017-01-25 日本曹達株式会社 防蟻性能試験用器具
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN109071627B (zh) 2016-02-05 2023-04-04 奥里尼斯生物科学私人有限公司 Cd8结合剂
WO2017153402A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
IL268346B2 (en) 2017-02-06 2024-08-01 Orionis Biosciences BV Targeted chimeric proteins and their uses
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3664829A4 (de) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. Pd-1- und pd-l1-bindemittel
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
CA3069992A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Clec9a binding agents and use thereof
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
CN113767115A (zh) 2019-03-28 2021-12-07 奥里尼斯生物科学股份有限公司 治疗性干扰素α1蛋白

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002863A1 (en) * 1983-12-23 1985-07-04 The Australian National University CLONING OF cDNA AND EXPRESSION OF MURINE-INTERLEUKIN-3
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
EP0276846A3 (de) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Derivate des koloniestimulierenden Faktors
OA09736A (en) * 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".

Also Published As

Publication number Publication date
DK0489116T3 (da) 1994-05-02
NO920703D0 (no) 1992-02-21
DE69007975T2 (de) 1994-07-21
NO301888B1 (no) 1997-12-22
FI920764A0 (fi) 1992-02-21
ES2055445T3 (es) 1994-08-16
DE69007975D1 (de) 1994-05-11
JPH05500806A (ja) 1993-02-18
AU6424090A (en) 1991-04-03
DD297188A5 (de) 1992-01-02
WO1991002754A1 (en) 1991-03-07
EP0489116B1 (de) 1994-04-06
EP0489116A1 (de) 1992-06-10
JP3115318B2 (ja) 2000-12-04
NO920703L (no) 1992-04-14
AU632372B2 (en) 1992-12-24

Similar Documents

Publication Publication Date Title
ATE103932T1 (de) Fusionsprotein bestehend aus gm-csf und il-3.
DE69933216D1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
ATE327254T1 (de) Interferon-beta fusionsproteine und deren verwendungen
MY102472A (en) Preparation of funtional human urokinase proteins.
DE3586313D1 (de) Konjugate von pharmazeutisch nuetzlichen proteinen.
AU3321595A (en) Recombinant production of biologically active peptides and proteins
BR9407583A (pt) Processos para produzir uma proteina bcl-2 mutante para identificar agentes modulantes de bcl-2 candidatos um bcl-2 mutante e proteinas bcl-2 mutantes e para inibir a atividade repressora de morte de células de bcl-2 e polipeptideo bcl-2 mutante
DE3571552D1 (en) Preparation containing stabilized polypeptide having gamma-interferon activity
IT1175508B (it) Un plasmide ricombinante, un microorganismo trasformante un segmento di polideossiribonucleotide, un procedimento per produrre una proteina biologicamente attiva e la proteina cosi' prodotta
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
FI954657A (fi) Biologisesti aktiivisia polypeptidifuusiodimeereja
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
ATE380873T1 (de) Prenylcystein carboxyl methyl-transferase, dns, welche für selbige kodiert, und ein verfahren zur suche nach hemmstoffen
DK109590D0 (da) Biologisk aktivt protein
DE68925304D1 (de) Minimale Derivatisierung von Proteinen
FI953422A0 (fi) Autolysoivia fuusioproteiineja hyväksikäyttävät ilmentämisjärjestelmät ja uusi pelkistävä polypeptidi
EP0669933A4 (de) Reinigung von fusionsproteinen, die gm-csf und il-3 enthalten.
MY114223A (en) Fusion proteins comprising gm-csf and il-3
NO891926L (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
ATE291629T1 (de) Expressionssystem für die sekretion von bioaktivem, menschlichem granulozyt-makrophagem koloniestimulierungsfaktor (gm-csf) und anderen heterologen proteinen aus streptomyces
IL96688A0 (en) Expression of delta-endotoxin proteins
FI944997A0 (fi) Parannettu rekombinantti-proteiinien tuotanto
AU1996388A (en) Proteins and protein compositions and their use
FI902700A0 (fi) Vaevnadplasminogenaktivatorderivat.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee